GBV 006

Drug Profile

GBV 006

Alternative Names: GBV-006

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University School of Medicine
  • Developer Globavir Biosciences
  • Class Antivirals
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ebola virus infections
  • Phase I Dengue
  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Dengue in USA (unspecified route) before September 2016
  • 01 Sep 2016 Phase-II clinical trials in Ebola virus infections in USA (unspecified route) before September 2016
  • 01 Sep 2016 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top